CardioLogical Solutions Is “Accessorizing” a Potential $3 Billion Market by...
Privately held CardioLogical Solutions is an emerging cardiovascular company formed this month by the merger of Emboline and VasoStitch. The company is developing a comprehensive suite of technologies...
View ArticleHot Stocks Watch: ADVENTRX Pharmaceuticals — Sickle Cell Anemia, Endothelial...
ADVENTRX (NYSE: ANX), a San Diego-based biopharmaceutical company, has made some strides in the development of a product candidate designed to treat genetic hematoma disorders, specifically sickle cell...
View ArticleJan Medical’s Nautilus Neurowave Platform Could Be a Game-Changer for Quickly...
Every 21 seconds, someone suffers a serious brain injury, such as a stroke, which is the third-leading cause of death in the United States and the leading cause of long-term disability. Today, Jan...
View ArticleVascular Nanotransfer Technologies Poised for Breakthrough Interventional...
Vascular Nanotransfer Technologies (VNT) says it has developed the industry’s most versatile Drug-Coated-Balloon (DCB) platform designed to deliver a wide variety of drugs for best-in-class DCB...
View Article2013, A Year for Point-of-Care Diagnostics Growth
Response Biomedical Corp. (RBM.TO)(RPBIF) is bringing in 2013 with a bang announcing their 2nd US distribution deal since the 1st week in January. Earlier in the month Response Biomedical entered a...
View ArticleSpine Surgeons Establish Uganda Spine Surgery Mission
“On my second trip to Uganda in 2005 I operated on a 15-year-old girl who had fallen out of a mango tree and broke her neck. She was essentially a paraplegic,” recalls Dr. Isador “Izzy” Lieberman, a...
View ArticleAmarantus Bioscience February Update
As part of our ongoing efforts to introduce our readers to intriguing investment opportunities, OneMedPlace has published an update of Amarantus Bioscience (AMBS). In our February Report, we discuss...
View ArticlePDUFA: March 31 – Invokana
The US Food and Drug advisory panel has voted for the preliminary approval of Invokana (canagliflozin), Johnson and Johnson’s new type 2 diabetes drug, in a 10 to 5 vote. On the table during the...
View ArticleVIDEO: Aptiv Solutions CEO Discusses Clinical Trials Guidelines, Unmet Need
Aside from re-defined financing structures, the most important issue facing life sciences EGCs is the need to increase clinical trial efficiency and productivity so that development budgets are used...
View ArticleMarch 2013: Santarus’ Uceris – Ulcerative Colitis
Last month, Santarus, Inc's Uceris for ulcerative colitis received FDA approval, and the company has announced a planned launch in March 2013. Santaurs has already begun adding 85 new positions to its...
View ArticleVIDEO: BDO’s Aftab Jamil Discusses Significant Changes in Life Sciences...
Aftab Jamil of BDO spoke with OneMedTV during the 6th Annual OneMedForum in January to discuss the state of life sciences investment, and how companies can formulate new strategies to attract a...
View ArticleWhen Eating Is Deadly for Children
ALLERGY is a burgeoning disease, and food allergies represent the segment where life can be directly threatened. In the U.S., more than three million people are allergic to peanut. Indeed, peanut...
View ArticleOneMedForumNY 2013, June 26-27
NEW YORK, October 3, 2012 – OneMedPlace has announced programming themes for its 6th Annual OneMedForum, taking place January 7-9th, 2013, at the Sir Francis Drake Hotel in San Francisco.
View ArticleWord on the Street:The Buy-Side View for 2013
The BIO CEO Investor Conference remains one of the most important events for companies, investors and industry executives to explore partnerships, raise capital, network or simply gain some useful,...
View ArticleActium BioSystems: Revolutionizing Drug Delivery for Oncology Hyperthermia
WHAT IF there were a way to give cancer a ‘fever’ to enhance the results of chemotherapy and radiation? There is, says Actium BioSystems...
View ArticleRELEASE: Glysure Earns ISO 13485 Certification
GlySure Limited, developer of in-hospital continuous blood glucose monitoring systems, today announced that it has achieved ISO 13485 certification, the global standard for the requirements of a...
View ArticleMeaningful Use, The Affordable Care Act, Sequestration, and Medical Devices
The Healthcare ecosystem in the United States is changing dramatically due to significant regulations and legislation. Though Obamacare gets the most attention for its impact on patient care and...
View ArticlePDUFA: Kadcyla, Immunogen – Metastasized Breast Cancer
Metastasized breast cancer now has a new therapy on the market, though it remains to be seen whether noticeably dangerous side effects may prevent widespread use. Trastuzumab emtansine (T-DM1) or...
View ArticleProtected: Intelgenx Management Interview
There is no excerpt because this is a protected post.
View ArticleAcadia Forges Forward With Pimavanserin
On March 12, 2013, Acadia Pharmaceuticals (ACAD) reported financial results for the fourth quarter and full year 2012. Total revenues in the quarter were $0.4 million, essentially in-line with our...
View Article
